|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-4-10
|
|
pubmed:abstractText |
The authors assessed the feasibility and construct validity of the contingent valuation method for measuring the monetary value to healthy enrollees in a health maintenance organization of a new drug, filgrastim, as prophylaxis against febrile neutropenia after chemotherapy treatment for cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0025-7079
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
370-84
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9520961-Adult,
pubmed-meshheading:9520961-Algorithms,
pubmed-meshheading:9520961-Analysis of Variance,
pubmed-meshheading:9520961-Attitude to Health,
pubmed-meshheading:9520961-Feasibility Studies,
pubmed-meshheading:9520961-Female,
pubmed-meshheading:9520961-Fever,
pubmed-meshheading:9520961-Financing, Personal,
pubmed-meshheading:9520961-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9520961-Health Maintenance Organizations,
pubmed-meshheading:9520961-Humans,
pubmed-meshheading:9520961-Male,
pubmed-meshheading:9520961-Neutropenia,
pubmed-meshheading:9520961-Patient Acceptance of Health Care,
pubmed-meshheading:9520961-Pennsylvania,
pubmed-meshheading:9520961-Questionnaires,
pubmed-meshheading:9520961-Recombinant Proteins,
pubmed-meshheading:9520961-Risk
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care.
|
|
pubmed:affiliation |
Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
